Our Brands

Since 1992, we have been distributing a wide range of in vitro diagnostic and clinical products on the Czech and Slovak markets. An emphasis on quality, a personal approach and maximum customer support have enabled us to become a leading player on the domestic market.

We offer a complete range of IVD – from immunochemistry through clinical biochemistry, haematology, microbiology to molecular biology.

In addition to the headquarters in the Czech Republic, we are also represented in Slovakia.

BioVendor Slovakia s.r.o. offers customers a comprehensive portfolio of products and services – from the distribution of diagnostic kits to turnkey laboratory equipment.

Since its founding in 1995, our BioVendor R&D division has been dedicated to research. It continues its efforts in development, production and distribution of immunodiagnostic and molecular diagnostic products in more than 25 clinical areas. Each one of our 70 employees makes the development of almost 200 immunodiagnostic ELISA kits possible.

One of the pillars of our activity is the introduction of the results of basic research into routine diagnostics. We cooperate with research and scientific institutions, we are members of professional consortia – we help direct scientific activities to address the needs of immunodiagnostic practice. We are currently focusing on two main areas: exploiting the diagnostic potential of microRNAs and introducing automated solutions for innovative biomarkers.

In addition to our headquarters in the Czech Republic, we operate the branch for USA, Canada and Mexico:

BioVendor LLC – Asheville, North Carolina, USA

The TestLine Clinical Diagnostics company was founded in 1993. During our more than 25 years in business, we have become one of the leading players on the IVD market with a wide portfolio of our own products and services.

We take an innovative approach based on long-term experience. The focus of our portfolio is on products for the ELISA and BLOT methods. The results of our development efforts in the field of laboratory automation are the popular SmartELISA kits and our own Microblot-Array multiplex solution.

At ViennaLab Diagnostics GmbH, we focus on the development and production of IVD assays focused on genetic defects and predispositions, pharmacogenetics, the human microbiome and oncological diseases.

Our original focus since 1990 has been the development and distribution of radioimmunoassays. Over the years, our focus has shifted to the development of reverse hybridisation and real-time PCR assays based on the TaqMan molecular diagnostics platform. We are currently working on the development of NGS technology, where we are expanding our portfolio for innovative parameters for testing the microbiome and oncological diseases.

Since its founding, ViennaLab has been characterised by a unique combination of scientific know-how and a human approach. This legacy of the company's founders has become an integral part of our DNA.

We have been developing, manufacturing and distributing products for clinical diagnostics for more than 35 years. We are one of the world's largest producers of radioimmunodiagnostic products. The main pillars of our manufacturing programme are products based on RIA and ELISA technology, including reagents for automated RIA and ELISA analysers. A special feature of our portfolio is panels for diagnostics of vitamin D, steroids, androgens and many other parameters. We also offer tools for automation of ELISA and RIA analyses.

Our main goal is to bring to the market reliable and accurate immunoassays and diagnostic tools and thus contribute to the fulfilment of our common vision of more effective diagnostics.

We strive to accelerate the delivery of modern, personalized diagnostics. Our mission is to bring a powerful combination of innovative solutions for molecular diagnostics, the human approach and scientific know-how to the market.

In close cooperation with other teams at the BioVendor Group, we look for ways to implement revolutionary technologies into routine laboratory practice. We are constantly expanding the portfolio of panels for the NGS method, we use predictive miRNA biomarkers for diagnostics, and we are co-developing the LAMP method.

We believe that continuous development and innovation are the way to fulfil the BioVendor Group's vision - faster, more accessible and more reliable diagnostics for patients all over the world.